Skip to main content
HR 2087 116th Congress House Health Administrative law and regulatory procedures Civil actions and liability Congressional oversight Consumer affairs Health care costs and insurance Health information and medical records Insurance industry and regulation Medicare Prescription drugs Retail and wholesale trades

Drug Price Transparency Act

Introduced: April 4, 2019 Introduced by: Doggett, Lloyd Democratic · Texas See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 21, 2019
Subcommittee Hearings Held.
Apr 5, 2019
Referred to the Subcommittee on Health.
Apr 4, 2019
Referred to the Subcommittee on Health.
Apr 4, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Drug Price Transparency Act

This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

What's happening now May 21, 2019

Subcommittee Hearings Held.

 Related & companion bills 6
  • HR 19 Related bill Lower Costs, More Cures Act of 2019
  • HR 2113 Related bill Prescription Drug STAR Act
  • HR 2296 Related bill More Efficient Tools to Realize Information for Consumers Act
  • S 2051 Related bill Strengthening Average Sales Price Reporting Act of 2019
  • S 3129 Related bill Lower Costs, More Cures Act of 2019
  • HR 1570 Related bill Removing Barriers to Colorectal Cancer Screening Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Republican 1
R
Buchanan, Vern
Florida · Apr 4, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2087: Drug Price Transparency Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-2087/
MLA
"H.R. 2087: Drug Price Transparency Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-2087/.
Bluebook (legal)
H.R. 2087, 116th Cong. (2026), https://openamerica.io/bill/116-HR-2087/.
Markdown link
[H.R. 2087: Drug Price Transparency Act](https://openamerica.io/bill/116-HR-2087/)
Report a problem